

Amendments to the Claims

Please amend claims 3, 5, and 6 as indicated in the following Listing of Claims

Listing of Claims

Claim 1. (Original) A method for treating a subject for an inflammatory condition which results from eosinophil accumulation which comprises generating an active immune response in the patient comprising autoantibodies to eotaxin and IL-5.

Claim 2. (Original) A method of treating a subject for a condition which results from asthma, allergy or allergic disease comprising generating an immune response in the subject to eotaxin and IL-5.

Claim 3. (Currently amended) An immunogenic composition comprising eotaxin or a peptide fragment thereof and IL-5 or a peptide fragment thereof coupled to an immunogenic protein-carrier.

Claim 4. (Original) An immunogenic composition comprising a T-cell epitope, an epitope derived from IL-5 and an epitope derived from eotaxin.

Claim 5. (Currently amended) An immunogenic composition according to claim 3 for the treatment of asthma, allergy or allergic disease comprising eotaxin or a portion thereof and IL-5 or a portion thereof conjugated to an immunogenic protein carrier.

Claim 6. (Currently amended) A method of producing the composition of claim 3, 4, ~~or 5~~ which comprises conjugating coupling the eotaxin or a portion thereof and the IL-5 or a portion thereof to the immunogenic carrier.

Claim 7. (Original) A method of treating a disorder involving an immunomodulatory pathway comprising multiple cytokines the method comprising actively immunizing a subject against two or more cytokines

in the pathway so as to elicit autoantibodies in the subject which can bind to and modulate the activities of the cytokines.

Claim 8. (Original) The method of claim 7 wherein the pathway is the Th-2 pathway.

Claim 9. (Original) The method of claim 8 wherein the subject is actively immunized against IL-5 and eotaxin.

Claim 10. (Original) A method for treating a subject for a condition mediated by eotaxin, which comprises generating an active immune response in the subject to eotaxin and at least one cytokine selected from the group consisting of eotaxin-2, eotaxin-3, IL-4, IL-5, IL-9 or IL-13.

Claim 11. (Original) The method of claim 10 wherein the condition mediated by eotaxin is asthma, allergy or allergic disease.

Claim 12. (Original) The immunogenic composition of claim 5 comprising at least one peptide sequence selected from the peptide sequences set forth in SEQ ID NOS 1-38, 42-61 and 117-121 and 130-132 and at least one peptide sequence selected from the peptide sequences set forth in SEQ ID NOS 62-116 and 122-123.

Claim 13. (Original) A method of ameliorating eosinophilia in a human subject which comprises downregulating eotaxin and concurrently down regulating a cytokine selected from the group consisting of eotaxin-2, eotaxin-3, IL-4, IL-5, IL-9, or IL-13.

Claim 14. (Original) A multivalent immunogenic composition for actively immunizing a subject to treat a Th-2 immune disorder comprising an immunogenic carrier conjugated to a plurality of peptide epitopes derived from two or more Th-2 cytokines.

Claim 15. (Original) The composition of claim 14 wherein the Th-2 cytokines are selected from the group consisting of eotaxin-1, eotaxin-2, eotaxin-3, IL-4, IL-5, IL-9 or IL-13.